New Tools for the Prevention of Cardiovascular Diseases and Disorders in Chronic Kidney Disease    

The consortium will apply the novel tools “proteomics, peptidomics, metabonomics and genotyping”, which allow assessing the complete transcription and translation of the genomic capital to elucidate the genetic and physiological background of CVD in CKD patients. This approach is focused on human samples i.e. tissues, cells and body fluids, as humoral targets are altered in CVD of CKD patients.

NTCVD applies "forward genetics" from phenotype to gene to remedy the causes of the enormously accelerated cardiovascular morbidity and death in CKD (stage 3-5) and to develop novel diagnostics and therapeutics, based on molecular genotyping and phenotyping.

This will be done
(A) by elucidating the role of recently identified mediators relating to CVD in CKD by using bioassay approaches and pattern analysis of CKD patient samples, and

(B) by the identification of yet unknown mediators.

Findings and results will be translated directly into new diagnostic and therapeutic devices for the prevention and treatment of CVD in CKD by collaborative efforts of the industry partners (one SME, one industrial company) within NTCVD.